Good morning :)
Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Ltd

LALPATHLAB Share Price

NSE
1,618.3018.37% (+251.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹22,840 cr, stock is ranked 324

Stock is 1.79x as volatile as Nifty

LALPATHLAB Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹22,840 cr, stock is ranked 324

Stock is 1.79x as volatile as Nifty

LALPATHLAB Performance & Key Metrics

LALPATHLAB Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
45.2510.351.79%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
39.945.920.57%

LALPATHLAB Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
82%
Analysts have suggested that investors can buy this stock

from 22 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

LALPATHLAB Company Profile

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.

Investor Presentation

View older View older 

Apr 30, 2026

PDF
View Older Presentations

LALPATHLAB Similar Stocks (Peers)

Compare with peers Compare with peers 

LALPATHLAB Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
75.94
75.94
1Y Return
9.45%
9.45%
Buy Reco %
89.66
89.66
PE Ratio
89.83
89.83
1Y Return
9.57%
9.57%
Buy Reco %
86.96
86.96
PE Ratio
90.00
90.00
1Y Return
34.63%
34.63%
Buy Reco %
83.33
83.33
PE Ratio
93.37
93.37
1Y Return
38.84%
38.84%
Buy Reco %
100.00
100.00
PE Ratio
45.41
45.41
1Y Return
0.35%
0.35%
Buy Reco %
83.33
83.33
Compare with Peers

LALPATHLAB Sentiment Analysis

LALPATHLAB Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

LALPATHLAB Stock Summary · February 2026

In Q3 FY26, the company achieved a 10.6% year-over-year revenue growth, bolstered by operational excellence initiatives that introduced over 15 new tests, despite facing challenges from lower-than-expected patient volumes due to seasonal factors. The launch of innovative programs like Sovaaka and Swasthfit has driven significant revenue, particularly in Tier 2 and Tier 3 markets, although pricing dynamics and margin pressures remain a concern. With a strong EBITDA margin of 27.2%, the company is strategically investing in capital expenditures to enhance its diagnostic capabilities, particularly in radiology, while maintaining a focus on sustainable growth through a scalable franchise model. As the healthcare landscape shifts towards preventive care, the company is well-positioned to capitalize on emerging opportunities, despite the ongoing challenges in the diagnostics sector.

LALPATHLAB Stock Growth Drivers
LALPATHLAB Stock Growth Drivers
6
  • Enhanced Diagnostics Ecosystem

    The company has made significant strides in enhancing its diagnostics ecosystem, focusing on accessibility and

  • Clinical Advancements and New Test Introductions

    In the current quarter, the company introduced over 15 new tests, including more than five

LALPATHLAB Stock Challenges
LALPATHLAB Stock Challenges
5
  • Decline in Profit Metrics

    The company reported a decline in profit before tax (PBT) for Q3 FY26, which was

  • Impact of Seasonal Factors

    The current quarter has been adversely affected by seasonal factors, particularly impacting volumes related to

LALPATHLAB Forecast

LALPATHLAB Forecasts

Price

Revenue

Earnings

LALPATHLAB

LALPATHLAB

Income

Balance Sheet

Cash Flow

LALPATHLAB Income Statement

LALPATHLAB Income Statement

Loading...

Quarterdec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026
Total Revenue557.20563.80622.50682.10621.80628.40697.90755.40684.20726.70
Operating & Other expensessubtract398.30400.70431.90457.70442.70433.60477.50506.50510.60515.90
Depreciation/Amortizationsubtract36.0036.6034.7035.3035.5036.4034.6040.5042.1044.60
Interest & Other Itemssubtract7.006.606.006.005.305.004.704.807.206.10
Taxes & Other Itemssubtract34.6035.4043.5053.9041.60-1.4048.7053.0033.8028.80
EPS4.895.076.407.765.809.297.949.035.427.86

LALPATHLAB Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

Apr 30PDF
Jan 30PDF
Oct 31PDF
Jul 31PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

Jan 30PDF
Oct 23PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 8PDF
Jul 27PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 11PDF
Nov 8PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

LALPATHLAB Stock Peers

LALPATHLAB Past Performance & Peer Comparison

LALPATHLAB Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dr. Lal PathLabs Ltd45.2510.351.79%
Apollo Hospitals Enterprise Ltd75.949.890.17%
Max Healthcare Institute Ltd89.8310.300.15%
Fortis Healthcare Ltd90.007.600.11%

LALPATHLAB Stock Price Comparison

Compare LALPATHLAB with any stock or ETF
Compare LALPATHLAB with any stock or ETF
LALPATHLAB
Loading...

LALPATHLAB Holdings

LALPATHLAB Shareholdings

LALPATHLAB Promoter Holdings Trend

LALPATHLAB Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LALPATHLAB Institutional Holdings Trend

LALPATHLAB Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 3.11%

Tickertape Separator

LALPATHLAB Shareholding Pattern

LALPATHLAB Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.21%18.62%2.76%17.18%8.22%

Jun 2025

Sep 2025

Dec 2025

Mar 2026

LALPATHLAB Shareholding History

LALPATHLAB Shareholding History

Dec '24MarJunSepDec '25Mar26.82%23.91%21.68%21.86%20.29%17.18%

Mutual Funds Invested in LALPATHLAB

Mutual Funds Invested in LALPATHLAB

No mutual funds holding trends are available

Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.4015%0.60%-0.02%48/69 (-2)
1.4715%1.64%0.21%9/64 (0)
0.9754%0.97%-0.02%60/83 (-1)

Compare 3-month MF holding change on Screener

LALPATHLAB Insider Trades & Bulk Stock Deals

LALPATHLAB Insider Trades & Bulk Stock Deals

Loading...

smallcases containing LALPATHLAB stock

smallcases containing LALPATHLAB stock

Looks like this stock is not in any smallcase yet.

LALPATHLAB Events

LALPATHLAB Events

LALPATHLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LALPATHLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.79%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹17.94 every year

Dividends

Corp. Actions

Announcements

Legal Orders

LALPATHLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LALPATHLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.79%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹17.94 every year

LALPATHLAB Upcoming Dividends

LALPATHLAB Upcoming Dividends

No upcoming dividends are available

LALPATHLAB Past Dividends

LALPATHLAB Past Dividends

Cash Dividend

Ex DateEx DateFeb 5, 2026

Interim 3
Interim 3 | Div/Share: ₹3.50

Dividend/Share

3.50

Ex DateEx Date

Feb 5, 2026

Cash Dividend

Ex DateEx DateNov 7, 2025

Interim 2
Interim 2 | Div/Share: ₹7.00

Dividend/Share

7.00

Ex DateEx Date

Nov 7, 2025

Cash Dividend

Ex DateEx DateAug 6, 2025

Interim
Interim | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Aug 6, 2025

Cash Dividend

Ex DateEx DateJun 6, 2025

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Jun 6, 2025

Cash Dividend

Ex DateEx DateFeb 5, 2025

Interim 3
Interim 3 | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Feb 5, 2025

LALPATHLAB Stock News & Opinions

LALPATHLAB Stock News & Opinions

Earnings
Dr Lal Pathlabs consolidated net profit declines 15.18% in the March 2026 quarter

Net profit of Dr Lal Pathlabs declined 15.18% to Rs 131.30 crore in the quarter ended March 2026 as against Rs 154.80 crore during the previous quarter ended March 2025. Sales rose 16.61% to Rs 702.70 crore in the quarter ended March 2026 as against Rs 602.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 3.63% to Rs 504.80 crore in the year ended March 2026 as against Rs 487.10 crore during the previous year ended March 2025. Sales rose 12.25% to Rs 2762.90 crore in the year ended March 2026 as against Rs 2461.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales702.70602.60 17 2762.902461.40 12 OPM %26.5828.05 -28.3228.26 - PBDT204.70189.80 8 861.00766.60 12 PBT160.10153.40 4 699.20624.70 12 NP131.30154.80 -15 504.80487.10 4 Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Board of Dr Lal Pathlabs approves incorporation of WoS in Dubai

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the incorporation of wholly owned subsidiary company in Dubai in the name and style of Dr Lal Pathlabs FZCO.

3 days agoCapital Market - Live
Corporate
Board of Dr Lal Pathlabs approves acquisition of Shahbazkers Diagnostic Centre

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre (SDCPL) from its existing Shareholders. Post acquisition, SDCPL shall become a wholly owned subsidiary of the company.

3 days agoCapital Market - Live
Corporate
Dr Lal Pathlabs fixes record date for final dividend

Dr Lal Pathlabs has fixed 26 June 2026 as record date for payment of final dividend of Rs 4 per equity share for FY 2026.

3 days agoCapital Market - Live
Corporate
Dr. Lal PathLabs schedules AGM

Dr. Lal PathLabs announced that the 32th Annual General Meeting(AGM) of the company will be held on 25 July 2026.

3 days agoCapital Market - Live
Corporate
Board of Dr. Lal PathLabs recommends Final Dividend

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 April 2026, has recommended a Final Dividend of Rs.4 per share (i.e.40%), subject to the approval of the shareholders.

3 days agoCapital Market - Live
Spotlight
Volumes soar at Dr Lal Pathlabs Ltd counter

Torrent Power Ltd, Tube Investments of India Ltd, Godrej Consumer Products Ltd, HCL Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 22 April 2026.Dr Lal Pathlabs Ltd recorded volume of 8.65 lakh shares by 10:47 IST on BSE, a 104.67 times surge over two-week average daily volume of 8262 shares. The stock gained 0.59% to Rs.1,448.35. Volumes stood at 7214 shares in the last session.Torrent Power Ltd recorded volume of 2.35 lakh shares by 10:47 IST on BSE, a 9.08 times surge over two-week average daily volume of 25898 shares. The stock gained 1.87% to Rs.1,652.35. Volumes stood at 12663 shares in the last session.Tube Investments of India Ltd notched up volume of 58534 shares by 10:47 IST on BSE, a 5.46 fold spurt over two-week average daily volume of 10712 shares. The stock rose 2.45% to Rs.2,955.50. Volumes stood at 12907 shares in the last session.Godrej Consumer Products Ltd witnessed volume of 2.82 lakh shares by 10:47 IST on BSE, a 5.45 times surge over two-week average daily volume of 51732 shares. The stock increased 1.56% to Rs.1,141.95. Volumes stood at 57919 shares in the last session.HCL Technologies Ltd recorded volume of 10.56 lakh shares by 10:47 IST on BSE, a 4.55 times surge over two-week average daily volume of 2.32 lakh shares. The stock lost 9.44% to Rs.1,305.40. Volumes stood at 1.15 lakh shares in the last session.

1 week agoCapital Market - Live
Corporate
Dr. Lal PathLabs schedules board meeting

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 30 April 2026.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Dr. Lal PathLabs recommends Third Interim dividend

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 January 2026, inter alia, have recommended the Third Interim dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Dr Lal Pathlabs consolidated net profit declines 6.41% in the December 2025 quarter

Net profit of Dr Lal Pathlabs declined 6.41% to Rs 90.50 crore in the quarter ended December 2025 as against Rs 96.70 crore during the previous quarter ended December 2024. Sales rose 10.57% to Rs 659.80 crore in the quarter ended December 2025 as against Rs 596.70 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales659.80596.70 11 OPM %27.1725.81 - PBDT196.50173.80 13 PBT154.40138.30 12 NP90.5096.70 -6 Powered by Capital Market - Live

3 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Dr. Lal PathLabs Ltd (LALPATHLAB) today?

    The share price of LALPATHLAB as on 4th May 2026 is ₹1618.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Dr. Lal PathLabs Ltd (LALPATHLAB) share?

    The past returns of Dr. Lal PathLabs Ltd (LALPATHLAB) share are
    • Past 1 week: -5.84%
    • Past 1 month: 5.67%
    • Past 3 months: -3.00%
    • Past 6 months: -11.49%
    • Past 1 year: -1.25%
    • Past 3 years: 39.90%
    • Past 5 years: -6.76%

  3. What are the peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB)?
  4. What is the dividend yield % of Dr. Lal PathLabs Ltd (LALPATHLAB) share?

    The current dividend yield of Dr. Lal PathLabs Ltd (LALPATHLAB) is 1.79.

  5. What is the market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹22840.51 Cr as of 4th May 2026.

  6. What is the 52 week high and low of Dr. Lal PathLabs Ltd (LALPATHLAB) share?

    The 52-week high of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹1770 and the 52-week low is ₹1272.60.

  7. What is the PE and PB ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) stock?

    The P/E (price-to-earnings) ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) is 45.25. The P/B (price-to-book) ratio is 10.35.

  8. Which sector does Dr. Lal PathLabs Ltd (LALPATHLAB) belong to?

    Dr. Lal PathLabs Ltd (LALPATHLAB) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.

  9. How to buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares?

    You can directly buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.